CRUZIVAX – Vaccine for Prevention and Treatment of Trypanosoma Cruzi Infection

Vector-borne diseases, spread by organisms such as pathogen-carrying insects, account for more than 17 % of all infectious diseases and they disproportionately affect people in the poorest populations. One of those is Chagas disease, prevalent mainly in Latin American countries. In severe cases, Chagas disease can cause congestive heart failure and cardiac arrest.

CRUZIVAX is taking a needle-free vaccine candidate from preclinical trials in mice through to a Phase I clinical trial in healthy volunteers. Even better, the study includes low-cost manufacturing and a health economics analysis to support widespread access by healthcare systems in poor countries that are the most vulnerable.

CRUZIVAX is a multinational integrated consortium composed of 3 Universities, 3 publicly-funded Research Institutes and 5 SMEs with access to cutting edge knowledge, technologies and expertise in commercial exploitation. The partners are located in 6 European countries and in Argentina.

Learn more about iBET’s participation in this project here.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815418.